MBX Biosciences, Inc. announced the appointment of Laurie Stelzer as an independent director on the Company?s Board of Directors and as chairperson of the board?s audit committee. Laurie Stelzer brings decades of executive and financial leadership experience with extensive corporate governance, financial oversight, and accounting experience. Ms. Stelzer previously served as Chief Financial Officer of Kailera Therapeutics, a biotechnology company focused on GLP-1 therapeutics.
She also currently serves on the boards of directors of Sionna Therapeutics, Inc., PMV Pharmaceuticals, Inc., and Spyre Therapeutics, Inc. For over 25 years, Ms. Stelzer has held leadership roles in finance, treasury, global accounting, business development, project management, and site operations for a range of biopharmaceutical companies including as Chief Financial Officer of Orna Therapeutics, Inc., Mirati Therapeutics, Inc., Arena Pharmaceuticals, Inc., and Halozyme Therapeutics, Inc. She also held senior management roles at Shire Plc and Amgen, Inc., and previously served on the boards of directors of Surface Oncology, Inc. and Longboard Pharmaceuticals. Ms. Stelzer earned a B.S. in Accounting from Arizona State University and an M.B.A. from University of California, Los Angeles, Anderson School of Management. Effective as of January 20, 2026, Ms. Stelzer has been appointed to serve as a member of, and the chairperson of, the Audit Committee of the Board, to replace Ed Mathers as a member of the Audit Committee.
Ms. Stelzer has also been appointed to serve as a member of the Compensation Committee of the Board. The compositions of the NCG Committee and the Science and Medicine Committee remain unchanged.
